logo
explain how to read the page

The above diagram shows the color scheme of the layout in the main result page. The parent entities and officers are those entities, including individual and legal persons, have significant controls over the company in focus. The offspring entities and appointments are those entities that the company in focus can influence on.

Clicking the links on parent entities or officers, and offspring entities or managed companies will put them in focus and show upstream or downstream connections. In general, ascendant entities can be found by moving toward upstream, and descendant entities are by toward downstream. In this way, progenitor entities such as grandparent companies (parents of parent), sibling companies (children of parent), partner companies (parents of child), and progeny entities such as grandchild companies (children of child) can be found easily.

Jump to: Company in focus, Offsprings
Parent entities and officers 8
  • 1
    Patel, Haziq
    Director born in June 1974
    Individual (9 offsprings)
    Officer
    2015-02-04 ~ 2025-04-02
    OF - Director → CIF 0
    Mr Haziq Patel
    Born in June 1974
    Individual (9 offsprings)
    Person with significant control
    2017-02-04 ~ 2025-04-02
    PE - Has significant influence or control → CIF 0
  • 2
    Mcdonald, Andrew Michael
    Individual (2 offsprings)
    Officer
    2025-04-02 ~ now
    OF - Secretary → CIF 0
  • 3
    Akhtar, Mobeen
    Director born in October 1981
    Individual (3 offsprings)
    Officer
    2015-02-04 ~ 2025-04-02
    OF - Director → CIF 0
    Mr Mobeen Akhtar
    Born in October 1981
    Individual (3 offsprings)
    Person with significant control
    2017-02-04 ~ 2025-04-02
    PE - Has significant influence or control → CIF 0
  • 4
    Che, Ka Yan
    Director born in December 1980
    Individual (8 offsprings)
    Officer
    2015-02-04 ~ 2025-04-02
    OF - Director → CIF 0
    Mr Ka Yan Che
    Born in December 1980
    Individual (8 offsprings)
    Person with significant control
    2017-02-04 ~ 2025-04-02
    PE - Has significant influence or control → CIF 0
  • 5
    Mollison, Peter
    Director born in December 1980
    Individual (8 offsprings)
    Officer
    2015-02-04 ~ 2025-04-02
    OF - Director → CIF 0
    Mr Peter Mollison
    Born in December 1980
    Individual (8 offsprings)
    Person with significant control
    2017-02-04 ~ 2025-04-02
    PE - Has significant influence or control → CIF 0
  • 6
    Volle, Thierry Robert Andre
    Born in July 1958
    Individual (4 offsprings)
    Officer
    2025-04-02 ~ now
    OF - Director → CIF 0
  • 7
    Ellis, Benjamin James
    Born in May 1971
    Individual (3 offsprings)
    Officer
    2025-04-02 ~ now
    OF - Director → CIF 0
  • 8
    LUPIN HEALTHCARE (UK) LIMITED
    - now 06925119
    LUPIN (EUROPE) LIMITED - 2018-02-09
    LUPIN (UK) LIMITED - 2009-06-26
    The Urban Building Second Floor, 3-9 Albert Street, Slough, England
    Active Corporate (12 parents, 1 offspring)
    Person with significant control
    2025-04-02 ~ now
    PE - Ownership of shares – 75% or more → CIF 0
    PE - Ownership of voting rights - 75% or more → CIF 0
parent relation
Company in focus

RENASCIENCE PHARMA LIMITED

Period: 2015-02-04 ~ now
Company number: 09420886
Registered name
RENASCIENCE PHARMA LIMITED - now
Standard Industrial Classification
21100 - Manufacture Of Basic Pharmaceutical Products
Brief company account
Comprehensive Income/Expense
2,621,968 GBP2024-03-01 ~ 2025-03-31
1,081,020 GBP2023-03-01 ~ 2024-02-29
Equity
Called up share capital
200 GBP2025-03-31
300 GBP2024-02-29
100 GBP2023-03-01
Retained earnings (accumulated losses)
1,919,364 GBP2025-03-31
1,054,282 GBP2024-02-29
Equity
746,394 GBP2024-02-29
308,288 GBP2023-03-01
Average Number of Employees
42024-03-01 ~ 2025-03-31
42023-03-01 ~ 2024-02-29
Profit/Loss
1,310,984 GBP2024-03-01 ~ 2025-03-31
540,510 GBP2023-03-01 ~ 2024-02-29
Total Inventories
188,373 GBP2025-03-31
110,678 GBP2024-02-29
Cash and Cash Equivalents
902,272 GBP2025-03-31
347,858 GBP2024-02-29
Current Assets
1,819,281 GBP2025-03-31
578,539 GBP2024-02-29
Total assets
1,822,403 GBP2025-03-31
584,983 GBP2024-02-29
Total liabilities
862,621 GBP2025-03-31
336,185 GBP2024-02-29
Net Assets/Liabilities
959,782 GBP2025-03-31
248,798 GBP2024-02-29
Profit/Loss
Retained earnings (accumulated losses)
1,310,984 GBP2024-03-01 ~ 2025-03-31
540,510 GBP2023-03-01 ~ 2024-02-29
Comprehensive Income/Expense
Retained earnings (accumulated losses)
1,310,984 GBP2024-03-01 ~ 2025-03-31
540,510 GBP2023-03-01 ~ 2024-02-29
Dividends Paid
Retained earnings (accumulated losses)
-600,000 GBP2024-03-01 ~ 2025-03-31
-600,000 GBP2023-03-01 ~ 2024-02-29
Dividends Paid
-600,000 GBP2024-03-01 ~ 2025-03-31
-600,000 GBP2023-03-01 ~ 2024-02-29
Equity - Income/Expense Recognised Directly
Retained earnings (accumulated losses)
-600,000 GBP2024-03-01 ~ 2025-03-31
-600,000 GBP2023-03-01 ~ 2024-02-29
Equity - Income/Expense Recognised Directly
-600,000 GBP2024-03-01 ~ 2025-03-31
-600,000 GBP2023-03-01 ~ 2024-02-29
Property, Plant & Equipment - Depreciation Expense
3,923 GBP2024-03-01 ~ 2025-03-31
3,888 GBP2023-03-01 ~ 2024-02-29
Turnover/Revenue
3,684,407 GBP2024-03-01 ~ 2025-03-31
1,874,019 GBP2023-03-01 ~ 2024-02-29
Other Interest Receivable/Similar Income (Finance Income)
14,972 GBP2024-03-01 ~ 2025-03-31
2,346 GBP2023-03-01 ~ 2024-02-29
Interest Payable/Similar Charges (Finance Costs)
1,359 GBP2024-03-01 ~ 2025-03-31
30 GBP2023-03-01 ~ 2024-02-29
Tax Expense/Credit at Applicable Tax Rate
450,265 GBP2024-03-01 ~ 2025-03-31
179,539 GBP2023-03-01 ~ 2024-02-29
Corporation Tax Payable
Current
490,074 GBP2025-03-31
176,714 GBP2024-02-29
Net Deferred Tax Liability/Asset
-933 GBP2025-03-31
-933 GBP2024-02-29
Dividends Paid on Shares
600,000 GBP2024-03-01 ~ 2025-03-31
600,000 GBP2023-03-01 ~ 2024-02-29
Property, Plant & Equipment - Gross Cost
Plant and equipment
32,031 GBP2025-03-31
29,899 GBP2024-02-29
27,848 GBP2023-03-01
Property, Plant & Equipment - Accumulated Depreciation & Impairment
Plant and equipment
28,909 GBP2025-03-31
24,986 GBP2024-02-29
21,098 GBP2023-03-01
Property, Plant & Equipment - Increase From Depreciation Charge for Year
Plant and equipment
3,923 GBP2024-03-01 ~ 2025-03-31
3,888 GBP2023-03-01 ~ 2024-02-29
Intangible Assets - Gross Cost
Goodwill
1,531 GBP2024-02-29
3,063 GBP2023-03-01
Value of work in progress
188,373 GBP2025-03-31
110,678 GBP2024-02-29
Trade Debtors/Trade Receivables
719,886 GBP2025-03-31
106,607 GBP2024-02-29
Prepayments/Accrued Income
8,750 GBP2025-03-31
Trade Creditors/Trade Payables
143,414 GBP2025-03-31
73,640 GBP2024-02-29
Accrued Liabilities
10,375 GBP2025-03-31
1,420 GBP2024-02-29
Other Taxation & Social Security Payable
706,651 GBP2025-03-31
254,071 GBP2024-02-29
Par Value of Share
Class 1 ordinary share
12024-03-01 ~ 2025-03-31
Number of Shares Issued (Fully Paid)
Class 1 ordinary share
100 shares2025-03-31
100 shares2024-02-29
Cash at bank and in hand
902,272 GBP2025-03-31
347,858 GBP2024-02-29
  • RENASCIENCE PHARMA LIMITED
    Info
    Registered number 09420886
    The Urban Building Second Floor, 3-9 Albert Street, Slough, Berkshire SL1 2BE
    PRIVATE LIMITED COMPANY incorporated on 2015-02-04 (11 years 5 months). The status of the company number is Active.
    The last date of confirmation statement was made at 2026-04-02
    CIF 0
child relation
Offspring entities and appointments 0
  • Not found in our database.

qrcode

Privacy notice

Terms and conditions

The content of this website is protected by AgonGuard.

© 2022- Polylogarithmic Technology Ltd (Registered in England and Wales No. 14256313). All rights reserved.

Contains public sector information retrieved at 22 April 2026 and licensed under the Open Government Licence v3.0.